Aaron Josephson Discusses the Past, Present, and Future of FDA Approval for Digital Therapeutics (TIPS 2018)

Aaron Josephson is the senior director of ML Strategies, a consulting subsidiary of the law firm Mintz Levin. Prior to joining ML Strategies, he was a senior policy advisor at the FDA’s Center for Devices and Radiological Health. Here, he speaks about the legal and policy considerations surrounding FDA’s approach to regulating software and other digital health products.

These remarks were part of the 2018 Technology in Psychiatry Summit, an event sponsored by the McLean Institute for Technology in Psychiatry, which occurred November 1-2, 2018 at Harvard Medical School, Boston, Massachusetts. Part of panel discussion, De-Risking Digital Development: Unpacking the Innovation Pipeline in Substance Use Disorder Treatment.

Please visit mclean.org/itp to learn more about the McLean Institute for Technology in Psychiatry.